Within the study population, approximately 49% of patients were lost to follow-up or did not complete adjuvant treatment through 5 years. Fifty-two percent of patients switched to a different ...

In the CAPItello-291 trial of capivasertib plus fulvestrant, 73% of patients had already received a CDK4/6 inhibitor. As ...

Please provide your email address to receive an email when new articles are posted on . Endocrine Today has compiled a list of recent FDA news stories relating to endocrine practice. Drugs under ...

WASHINGTON—R. Scott Struthers, Ph.D., has been awarded the Endocrine Society’s John D. Baxter Prize for Entrepreneurship for his contributions to drug discovery and development programs for endocrine ...

Heart failure and type 2 diabetes are exquisitely intertwined. Their shared pathophysiology can accelerate debilitating outcomes for patients that clinicians struggle to prevent and treat. People with ...

A Camden, New Jersey, federal judge ruled that Teva Pharmaceuticals USA Inc.'s application to make a generic version of a drug called Korlym did not infringe on patents on the drug that are held by ...

SAN ANTONIO -- Patients with progressive advanced hormone receptor (HR)-positive breast cancer had significant improvement in progression-free survival (PFS) with an investigational selective estrogen ...

Breast cancer researchers from the Florida campus of The Scripps Research Institute (TSRI) have developed a novel approach for identifying how chemicals in the environment—called environmental ...

Joint Press Release from the European Society of Endocrinology (ESE) and the European Society for Paediatric Endocrinology (ESPE) and the Armenian Association of Paediatric Endocrinologists and the ...

LONDON--(BUSINESS WIRE)--Technavio has been monitoring the endocrinology drugs market and it is poised to grow by USD 24.78 billion during 2020-2024, progressing at a CAGR of almost 7% during the ...

Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX), a biopharmaceutical company specializing in oral endocrinology drugs, is attracting significant attention from investors and analysts alike as it ...